JAGUAR HEALTH INC (JAGX)

Company Profile

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The company is headquartered in San Francisco, California and currently employs 60 full-time employees. The company went IPO on 2015-05-13. The firm is focused on developing plant-based, sustainably derived prescription medicines for people and animals with gastrointestinal (GI) distress, including chronic and debilitating diarrhea. The company operates through two segments: human health and animal health. Human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. Animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. Its Canalevia-CA1 is used for chemotherapy-induced diarrhea in dogs. Its subsidiary includes Napo Pharmaceuticals, Inc., which focuses on developing and commercializing plant-based human pharmaceuticals.

Company Info

JAGUAR HEALTH INC

200 Pine Street Suite 400

San Francisco CALIFORNIA 94104

P: 14153718300

CEO: Lisa A. Conte

Employees: 60

Website: https://jaguar.health/